Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | FOS | P01100 | 2/20 | 0.31 |
| ▸ | JUN | P05412 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.31 |
| ▸ | RELA | Q04206 | 2/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337008 | 0.86 | EGLN1 (0.43) | EGLN1EGLN2EGLN3FOSJUN | |
| SCHEMBL336829 | 0.82 | EGLN1 (0.63) | EGLN1EGLN2EGLN3HIF1A | |
| SCHEMBL2439372 | 0.81 | EGLN1 (0.49) | EGLN1EGLN2EGLN3KMT2AMEN1 | |
| SCHEMBL2434232 | 0.81 | EGLN1 (0.54) | EGLN1HDAC6KMT2AMEN1HIF1A | |
| SCHEMBL336505 | 0.80 | ALDH1A1 (0.51) | EGLN1FOSJUNNFKB1NFKB2 | |
| SCHEMBL10085742 | 0.79 | EGLN1 (0.48) | EGLN1EGLN2EGLN3KMT2AMEN1 | |
| SCHEMBL12291858 | 0.75 | EGLN1 (0.53) | EGLN1KMT2AMEN1MAPTNPC1 | |
| SCHEMBL12291846 | 0.75 | EGLN1 (0.58) | EGLN1HDAC6NFKB1KMT2AMEN1 | |
| SCHEMBL337546 | 0.75 | EGLN1 (0.50) | EGLN1EGLN2EGLN3KMT2AMEN1 | |
| SCHEMBL2434564 | 0.74 | EGLN1 (0.52) | EGLN1HDAC6KMT2ARXRAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142509-B1 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8349868-B2 | Azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349868-B2 | Azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | EGLN3, HIF1AN, EGLN2 | EGLN1 6/4885EGLN2 3/4885EGLN3 1/4885 |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885EGLN2 3/4885EGLN3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.